{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T08:41:00Z","timestamp":1791103260154,"version":"4.1.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2009,5,1]],"date-time":"2009-05-01T00:00:00Z","timestamp":1241136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["La Presse M\u00e9dicale"],"published-print":{"date-parts":[[2009,5]]},"DOI":"10.1016\/j.lpm.2009.01.012","type":"journal-article","created":{"date-parts":[[2009,5,4]],"date-time":"2009-05-04T08:48:23Z","timestamp":1241426903000},"page":"799-807","source":"Crossref","is-referenced-by-count":20,"title":["Indications de l\u2019anakinra"],"prefix":"10.1016","volume":"38","author":[{"given":"Karine","family":"Chauffier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"London","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constance","family":"Beaudouin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Fautrel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 1","key":"10.1016\/j.lpm.2009.01.012_bib1","doi-asserted-by":"crossref","first-page":"i60","DOI":"10.1136\/ard.59.suppl_1.i60","article-title":"Biological role of interleukin 1 receptor antagonist isoforms","volume":"59","author":"Arend","year":"2000","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.lpm.2009.01.012_bib2","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1136\/ard.61.11.960","article-title":"Potential therapeutic uses of interleukin 1 receptor antagonists in human diseases","volume":"61","author":"Hallegua","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.lpm.2009.01.012_bib3","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1002\/art.10168","article-title":"Targeting interleukin-1 in the treatment of rheumatoid arthritis","volume":"46","author":"Dayer","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.lpm.2009.01.012_bib4","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1002\/1529-0131(199812)41:12<2196::AID-ART15>3.0.CO;2-2","article-title":"Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist","volume":"41","author":"Bresnihan","year":"1998","journal-title":"Arthritis Rheumatism"},{"key":"10.1016\/j.lpm.2009.01.012_bib5","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1002\/art.10141","article-title":"Treatment of rheumatoid arthritis with anakinra, a recombinant interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four week, multicenter, randomized, double-blind, placebo controlled trial","volume":"46","author":"Cohen","year":"2002","journal-title":"Arthritis Rheumatism"},{"key":"10.1016\/j.lpm.2009.01.012_bib6","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1136\/ard.2003.016014","article-title":"A multicentre, double blind, randomised, placebo controlled trial of anakinra, a recombinant interleukin-1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate","volume":"63","author":"Cohen","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.lpm.2009.01.012_bib7","first-page":"1538","article-title":"Effect of anakinra on functional status in patients with active rheumatoid arthritis receiving concomitant therapy with traditional disease modifying antirheumatic drugs: evidence from the OMEGA Trial","volume":"35","author":"Le Lo\u00ebt","year":"2008","journal-title":"J Rheumatol"},{"key":"10.1016\/j.lpm.2009.01.012_bib8","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1093\/rheumatology\/ken223","article-title":"Adjunctive anakinra in patients with active rheumatoid arthritis despite methotrexate, or leflunomide, or cyclosporin-A monotherapy: a 48-week, comparative, prospective study","volume":"47","author":"Karanikolas","year":"2008","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.lpm.2009.01.012_bib9","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1002\/art.20221","article-title":"Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully by methotrexate","volume":"50","author":"Genovese","year":"2004","journal-title":"Arthritis Rheumatism"},{"key":"10.1016\/j.lpm.2009.01.012_bib10","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.berh.2008.08.006","article-title":"Adult-onset Still disease","volume":"22","author":"Fautrel","year":"2008","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.lpm.2009.01.012_bib11","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1136\/ard.2007.076034","article-title":"Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France","volume":"67","author":"Lequerr\u00e9","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.lpm.2009.01.012_bib12","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1002\/art.23437","article-title":"The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis","volume":"58","author":"Gattorno","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.lpm.2009.01.012_bib13","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1093\/rheumatology\/ken030","article-title":"Anakinra treatment for systemic onset juvenile idiopathic arthritis (SOJIA)","volume":"47","author":"Ohlsson","year":"2008","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.lpm.2009.01.012_bib14","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1001\/archderm.144.3.392","article-title":"Autoinflammatory diseases clinical and genetic advances","volume":"144","author":"Farasat","year":"2008","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.lpm.2009.01.012_bib15","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.jbspin.2008.04.001","article-title":"Anakinra: New therapeutic approach in children with Familial Mediterranean Fever resistant to colchicine","volume":"75","author":"Roldan","year":"2008","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.lpm.2009.01.012_bib16","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1016\/S0140-6736(04)17401-1","article-title":"Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist","volume":"264","author":"Hoffman","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.lpm.2009.01.012_bib17","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1002\/art.23261","article-title":"Anakinra Improves Sensory Deafness in Janpanese Patient with Muckle-Wells Syndrome. Possibly by Inhibiting the Cryopyrin Inflammosome","volume":"58","author":"Yamazaki","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.lpm.2009.01.012_bib18","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1056\/NEJMoa055137","article-title":"Neonatal-Onset Multisystem Inflammatory Disease Responsive to Interleukin-1\u03b2 Inhibition","volume":"355","author":"Goldbach-Mansky","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2009.01.012_bib19","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1002\/art.23475","article-title":"Persistent Efficacy of Anakinra in Patients With Tumor Necrosis Receptor-Associated Periodic Syndrome","volume":"58","author":"Gattorno","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.lpm.2009.01.012_bib20","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1093\/rheumatology\/keh479","article-title":"Anakinra for flares of pyogenic arthritis in PAPA syndrome","volume":"44","author":"Dierselhuis","year":"2005","journal-title":"Rheumatology"},{"key":"10.1016\/j.lpm.2009.01.012_bib21","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1097\/MD.0b013e318190cfb7","article-title":"Long-term follow-up, clinical features, and quality of life in a series of 103 Patients With Hyperimmunoglobulinemia D syndrome","volume":"87","author":"van der Hilst","year":"2008","journal-title":"Medicine"},{"key":"10.1016\/j.lpm.2009.01.012_bib22","first-page":"2","article-title":"Sweet's syndrome-a comprehensive review of an acute febrile neutrophilic dermatosis","volume":"26","author":"Cohen","year":"2007","journal-title":"Orphaned J Rare Dis"},{"key":"10.1016\/j.lpm.2009.01.012_bib23","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1136\/ard.2006.068254","article-title":"Efficacy of anakinra, an IL1 receptor antagonist, in refractory Sweet Syndrome","volume":"67","author":"Delluc","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.lpm.2009.01.012_bib24","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1053\/berh.1999.0079","article-title":"Relapsing polychondritis","volume":"14","author":"Molina","year":"2000","journal-title":"Baillieres Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.lpm.2009.01.012_bib25","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1093\/rheumatology\/kel041","article-title":"Refractory relapsing polychondritis: rapid and sustained response in the treatment with an Il-1 receptor antagonist (anakinra)","volume":"45","author":"Vounotrypidis","year":"2006","journal-title":"Rheumatology"},{"key":"10.1016\/j.lpm.2009.01.012_bib26","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.jbspin.2008.02.011","article-title":"Efficacy of anakinra in patient with refractory relapsing polychondritis","volume":"75","author":"Wendling","year":"2008","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.lpm.2009.01.012_bib27","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.jbspin.2007.04.004","article-title":"The inflammasome, auto-inflammatory diseases, and gout","volume":"74","author":"P\u00e9trilli","year":"2007","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.lpm.2009.01.012_bib28","doi-asserted-by":"crossref","first-page":"R28","DOI":"10.1186\/ar2143","article-title":"A pilot study of IL-1 inhibition by anakinra in acute gout","volume":"92","author":"So","year":"2007","journal-title":"Arthitis Res Ther"},{"key":"10.1016\/j.lpm.2009.01.012_bib29","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1136\/ard.2007.073759","article-title":"Management of treatment resistant inflammation of acute on chronic tophaceous gout with anakinra","volume":"66","author":"McGonagle","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.lpm.2009.01.012_bib30","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1136\/ard.2005.048371","article-title":"Safety of extended treatment with anakinra in patients with rheumatoid arthritis","volume":"65","author":"Fleischmann","year":"2006","journal-title":"Ann Rheum Dis"}],"container-title":["La Presse M\u00e9dicale"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498209000876?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498209000876?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,20]],"date-time":"2018-12-20T05:56:45Z","timestamp":1545285405000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0755498209000876"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,5]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2009,5]]}},"alternative-id":["S0755498209000876"],"URL":"https:\/\/doi.org\/10.1016\/j.lpm.2009.01.012","relation":{},"ISSN":["0755-4982"],"issn-type":[{"value":"0755-4982","type":"print"}],"subject":[],"published":{"date-parts":[[2009,5]]}}}